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Abstract
Background: Half of all lower limb deep vein thrombi (DVT) in symptomatic ambulatory patients are located in
the distal (calf) veins. While proximal disease warrants therapeutic anticoagulation to reduce the associated risks,
distal DVT often goes untreated. However, a proportion of untreated distal disease will undoubtedly propagate or
embolize. Concern also exists that untreated disease could lead to long-term post thrombotic changes. Currently, it
is not possible to predict which distal thrombi will develop such complications. Whether these potential risks
outweigh those associated with unrestricted anticoagulation remains unclear. The Anticoagulation of Calf
Thrombosis (ACT) trial aims to compare therapeutic anticoagulation against conservative management for patients
with acute symptomatic distal deep vein thrombosis.
Methods: ACT is a pragmatic, open-label, randomized controlled trial. Adult patients diagnosed with acute distal
DVT will be allocated to either therapeutic anticoagulation or conservative management. All patients will undergo
3 months of clinical and assessor blinded sonographic follow-up, followed by 2-year final review. The project will
commence initially as an external pilot study, recruiting over a 16-month period at a single center to assess
feasibility measures and clinical event rates. Primary outcome measures will assess feasibility endpoints. Secondary
clinical outcomes will be collected to gather accurate data for the design of a definitive clinical trial and will
include: (1) a composite endpoint combining thrombus propagation to the popliteal vein or above, development
of symptomatic pulmonary embolism or sudden death attributable to venous thromboembolic disease; (2) the
incidence of major and minor bleeding episodes; (3) the incidence of post-thrombotic leg syndrome at 2 years
using a validated screening tool; and (4) the incidence of venous thromboembolism (VTE) recurrence at 2 years.
Discussion: The ACT trial will explore the feasibility of comparing therapeutic anticoagulation to conservative
management in acute distal DVT, within a modern cohort. We also aim to provide contemporary data on clot
propagation, bleeding rates and long-term outcomes within both groups. These results will inform the conduct of
a definitive study if feasibility is established.
Trial registration: Current Controlled Trials ISRCTN75175695
Keywords: Anticoagulants, embolism, lower extremity, venous thrombosis
Background
Venous thromboembolic (VTE) disease is an interna-
tional, topical and costly healthcare burden. Incidence
rates are equivalent to that of stroke within the western
hemisphere [1] and disease consequences can be as
severe. Recent studies addressing prognosis provide a
stark reminder of continuing poor outcome, quoting a
15% mortality rate at 3 months post diagnosis for VTE
involving the pulmonary vascular tract [2]. Outcome
from VTE confined to the lower extremities fares little
better, with a reported short-term all-cause mortality
between 7% and 15% [3]. Observational data suggests
reduced survival compared to control subjects after first
episode of symptomatic deep vein thrombosis. This
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trend has been shown to persist for up to 8 years post
diagnosis [4]. Clinical research demonstrating poor out-
come has led to a national focus on early diagnosis and
active prevention, with the creation of guidelines from
both the UK Health Technology Assessment (HTA)
group and the National Institute of Clinical Excellence
(NICE) within the last decade [5,6].
Despite the large body of research on VTE, contro-
versy still remains regarding many aspects of therapeutic
clinical practice. One such area is that of distal deep
vein thrombosis (DVT), a condition previously thought
to be of limited clinical significance. There are multiple
epidemiological studies suggesting distal thrombi consti-
tute approximately 50% of objectively diagnosed lower
limb disease in symptomatic ambulatory patients [7-9].
This proportion may be even higher in asymptomatic
disease or hospitalized patients [10]. However, the bene-
fits of intervention in distal disease remain poorly
researched, with conflicting international guidance on
investigation and treatment.
Some authors question the ability of ultrasound to
diagnose distal DVT. Indeed, recent meta-analyses have
consistently failed to show a pooled sensitivity for detec-
tion of distal thrombosis by ultrasound any higher than
75% [11,12]. This failing could well be related to the
potential pitfalls of the current gold standard: contrast
venography has been noted as a potential cause of DVT
and has many additional caveats, including extravasation
reactions, technical limitations and variable interobser-
ver reliability [13,14]. Despite these failings, many clini-
cians cite the poor sensitivity data and choose to base
their management strategies on serial compression ultra-
sound of the thigh, avoiding the distal veins altogether.
In the absence of sonographic progression to proximal
veins after 7 days, the presence of distal disease is pre-
sumed to be clinically irrelevant. Recent well conducted
studies report a non-significant difference in 3-month
VTE event rates between patients randomized to be
investigated by serial or complete leg ultrasound in sus-
pected DVT [15,16]. The British Society of Haematology
endorse this approach to suspected lower limb VTE in a
national guidance document [17]. Thus, many clinicians
withhold anticoagulation after serially negative proximal
ultrasound.
Conversely, it is also well recognized that a proportion
of untreated distal disease will propagate, embolize and/
or lead to chronic venous pathology. Current estimates
of proximal propagation in untreated patients range
between 0% and 29%, with some untreated patients
developing pulmonary emboli during short-term follow-
up [18]. The most relevant studies assessing complica-
tion rates in untreated patients can be seen in Table 1
[19-25]. There have also been previous reports of fatal
pulmonary embolism occurring within the 7 days after
initial negative proximal ultrasound in suspected disease
[26]. The potential to cause post-thrombotic syndrome
(PTS) is valid but as yet unquantified [27,28]. These
sequelae prompt some clinicians to advocate standard
therapeutic anticoagulation for all. Several international
organizations endorse this approach when diagnosis is
clarified [29-31].
It remains unclear whether the benefits of treatment
outweigh the potential harms. The only randomized
trial comparing conservative management to standar-
dized oral anticoagulation in distal DVT was per-
formed by Lagerstedt et al. in 1985 [19]. A total of 51
participants were included. The authors demonstrated
a 29% 3-month recurrence rate and a 32% 1-year
recurrence rate for conservatively managed patients
with distal DVT. The incidence of recurrence in war-
farinized patients was significantly lower, 0% at 3
months and 4% at 1 year. The results from this trial
have been much debated, with many authors highlight-
ing the small sample size, composite diagnostic stan-
dards and unequal baseline characteristics between
groups [32].
Recent studies using ultrasonography to detect recur-
rence or propagation have failed to replicate Lagerstedt
et al. ’s data. Using a limited treatment regimen of
reduced dose heparin for 4 weeks only, Parisi et al.
demonstrated a 2.9% propagation rate at 3-month fol-
low-up [33]. The blind, prospective CALTHRO study
has recently reported low rates of venous thromboem-
bolism/recurrence in untreated patients at 3 months,
noting an event rate of 7.8% (95% CI 3% to 17%) [23].
Schwarz et al. have demonstrated further reduced
event rates when selecting out low-risk distal DVT for
conservative treatment, with propagation in only 3.7%
of untreated patients [24]. However, no study has
attempted to definitively answer the question by per-
forming an adequately powered prospective rando-
mized controlled trial (RCT). This is highlighted by a
recent meta-analysis that notes the heterogeneity of
trial data and fails to provide a robust conclusion,
despite analyzing data from over 450 patients [34].
Equipoise remains, perhaps best highlighted by recent
European research noting the profound and continuing
regional variability in diagnostic and therapeutic
approach to distal DVT [35]. Recent articles have high-
lighted the need for robust evidence and called
urgently for further prospective RCT data to inform
clinical decision making [32,36,37].
We designed a trial to examine the feasibility of test-
ing the applicable null hypothesis: that therapeutic
anticoagulation for 3 months confers no significant clin-
ical benefit in the management of acute symptomatic
distal DVT, when compared to conservative treatment
alone.
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Methods
Study aims
The Anticoagulation of Calf Thrombosis (ACT) trial
aims to compare the incidence of venous thromboem-
bolic complications in patients with distal deep vein
thrombosis treated with either standard therapeutic
anticoagulation or conservative management.
Study design and setting
The study will be initially conducted as a prospective,
randomized, open-label, pragmatic, controlled trial
within the Emergency Department (ED) at Central Man-
chester University Hospitals NHS Foundation Trust.
The ED has an average annual attendance figure of
110,000. The trial will begin as an external pilot project,
recruiting distal DVT patients over a 16-month period
at a single center to assess feasibility and gather accurate
clinical outcome data. A study process flow chart is
given in Figure 1.
Ethical considerations
Ethical approval for this study has been obtained from
the North West Greater Manchester Central Research
Ethics Committee (ref: 10/H1008/97) as a Controlled
Trial of an Investigative Medicinal Product (CTIMP).
The Medicines and Healthcare products Regulatory
Agency (MHRA) have granted clinical trial authoriza-
tion. A Data Safety and Monitoring Board (DSMB)
including a leading expert in thrombosis/hemostasis will
be convened to evaluate data and comment on safety
within the trial. A Trust Steering committee will oversee
local trial conduct and governance. The study is subject
to all ongoing NHS Research and Development govern-
ance checks regarding CTIMP projects.
Study interventions
Patients randomized to trial group A will receive
immediate therapeutic anticoagulation with initial daily
administration of subcutaneous low molecular weight
heparin (LMWH), followed by 3 months oral standard
NHS anticoagulant pharmacotherapy. Pending UK adop-
tion of novel agents, oral anticoagulation will be
achieved with warfarin targeted to an international nor-
malized ratio (INR) of 2.5 (range 2.0 to 3.0). Patients
will be monitored by a dedicated anticoagulant clinic at
the study site and seen at regular intervals for INR test-
ing. Methods for adjusting warfarin dose and maintain-
ing target INR will be at the discretion of the
anticoagulant clinic service. Compliance will be evalu-
ated within treatment groups. Group A patients will
also receive grade 2 compression hosiery fitted exter-
nally through the orthotics department.
Group B trial patients will receive symptomatic treat-
ment only, in the form of simple analgesia and fitted
grade 2 compression hosiery.
Identification of eligible patients
All ambulatory patients with suspected DVT attending
the ED will undergo risk stratification, blood investiga-
tion and subsequent complete lower limb duplex com-
pression ultrasound (CUS), in line with standard
practice. Prior to ultrasonography, all patients with sus-
pected DVT will be provided with a patient information
sheet outlining the trial protocol.












Low-risk ambulatory patients with isolated calf
muscle thrombus
53 CUS 3 months 2/53 = 3.77%
Palareti et al.
2010 [21]
Symptomatic outpatients 65 CUS 3 months 5/64 = 7.8%
Macdonald et
al. 2003 [19]
Mostly symptomatic surgical and medical inpatients
(68.6%) with isolated calf muscle vein thrombus
135 CUS 3 months 4/135 = 3%
Schwarz et al.
2001 [23]
Symptomatic outpatients with isolated calf muscle
vein thrombosis
32 CUS 3 months 8/32 = 25%
Lohr et al.
1995 [18]
Mostly symptomatic surgical and medical inpatients
(59.4%)




Asymptomatic postoperative total hip replacement/
total knee replacement patients
41 CUS 12 months 7/41 = 17.1%
Lagerstedt et
al. 1985 [17]
Symptomatic medical patients 28 Isotopic uptake confirmed
by ascending
phlebography
90 days 8/28 = 29%
CUS = compression ultrasound; VTE = venous thromboembolic complication rate: this refers to ascending proximal extension of the thrombus to the popliteal
vein or development of symptomatic pulmonary embolism, except for the study by Schwarz et al. [23]. In this trial, patients were commenced on therapeutic
anticoagulation if the distal thrombus propagated to any of the deep calf veins. Many cases were therefore treated prior to potential popliteal extension.
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Patients will be managed in an ED thrombosis clinic
the same day, where they will be further counseled
regarding diagnosis and treatment options. The presence
of isolated thrombus in any of the peroneal, soleal, gas-
trocemial, or tibial veins on duplex CUS detected by an
accredited vascular technician, will constitute the
Figure 1 Summary of trial design/patient flow. Proximal DVT relates to acute thrombotic disease above the level of the trifurcation of the
popliteal vein. Chronic DVT relates to any reported thrombosis detected on prior documented ultrasound, previously treated, or with chronic
appearance on contemporary ultrasound exam. DVT = deep vein thrombosis.
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diagnosis of distal DVT. Patients with confirmed distal
disease will be screened for eligibility by a trained
researcher. Inclusion/exclusion criteria are documented
below. Only patients able to provide written informed
consent will be approached for inclusion. Demographic
data will be collected on case report forms, including
risk factors (permanent and temporary), provocation,
baseline blood tests and examination findings.
Inclusion criteria
• Aged 16 or above
• Symptomatic attendance to the Emergency Depart-
ment with atraumatic leg pain and/or swelling as the
principal complaint
• Objective diagnosis of distal deep vein thrombosis
by duplex vascular ultrasound
Exclusion criteria
• Hospitalised patients (all inpatients)
• Long term therapeutic anticoagulation
• Associated confirmed venous thromboembolic dis-
ease (Proximal leg DVT, PE or central vein
thrombosis)
• Contraindication to anticoagulation (presence of
active bleeding, recent haemorrhagic stroke or upper
gastrointestinal bleed)
• Active cancer
• Any other indication for anticoagulation according
to national/local guidance: prior confirmed and trea-
ted above knee DVT/PE, antiphospholipid syndrome
or symptomatic inherited thrombophilia.
• Pregnancy
• Chronic non propagating thrombus
• Previous enrollment to the ACT trial
Randomization technique
Randomization will occur after patient consent has been
taken. Participating patients will be assigned to one of
two groups by a remote, computerized, web-based ran-
domization sequence, constructed with variable per-
muted block size. Group A will be allocated to receive
therapeutic anticoagulation with standard pharma-
cotherapy, group B to receive conservative management.
All patients will be briefed in person and writing regard-
ing the clinical signs of extending DVT/PE and advised
to contact the trial team or return to the ED with any
concerns.
Blinding
This is an open-label study. Although previous trials
have used ‘sham’ anticoagulant clinics we feel use of pla-
cebo and frequent hospital visits to maintain blinding
would be potentially unethical and deleterious to
recruitment. Complications in the context of warfarini-
zation also need urgent treatment and an unblinding
protocol would naturally delay this.
All ultrasonographers will be blinded to allocation for
repeat scans. Clinical outcome measures are primarily
objective, which should minimize the risk of measure-
ment bias.
Patient follow-up procedures
Patients will return at 7 and 21 days for follow-up
duplex CUS and clinical review. Vascular radiology tech-
nicians will be blinded to treatment allocation for all
scans. Propagation of DVT to the level of the popliteal
vein (above the trifurcation) at any point post randomi-
zation will be considered as proximal extension and
result in immediate therapeutic anticoagulation. Patients
will be clinically reviewed and outcome data collected
when they attend for repeat CUS. Worsening symptoms
in the context of non-propagation above the trifurcation
will be assessed carefully and further investigations will
be dictated by clinical need.
At the end of the 3-month treatment period all sub-
jects will be followed up via medical record review and
structured telephone interview. An ED appointment will
be arranged if any queries or clinical concerns persist.
All patients will be encouraged to continue wearing
compression stockings daily for 2 years, as per current
evidence [38]. Suspicion of pulmonary VTE at any stage
will be investigated as per current practice and con-
firmed by Prospective Investigation Of Pulmonary
Embolism Diagnosis (PIOPED) reported V/Q scan or
computed tomography (CT)-pulmonary angiography
[39]. Any patient diagnosed with pulmonary VTE will
receive immediate therapeutic anticoagulation as per
current practice. Out of normal working hours, patients
will be advised to attend the ED with any concerns,
where a protocol for investigation of suspected pulmon-
ary embolism in ambulatory patients is already standard
practice.
Final clinical review and data collection will occur at 2
years post inclusion, regarding the incidence and sever-
ity of post thrombotic syndrome and the incidence of
DVT recurrence in all patients. The diagnosis and sever-
ity of PTS will be assessed using the standardized scor-
ing system validated by Villalta et al. [40].
Patient outcome measures
As an external pilot study, the primary endpoints for the
trial will constitute measures of feasibility only. A suc-
cessful pilot RCT seeks to collect data regarding process,
resources, management and scientific data [41]. Feasibil-
ity outcomes have been designed to reflect this. Clinical
measures of treatment effect and safety will be recorded
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as secondary outcomes, in order to inform further sam-
ple size calculations and data inference for potential
future multicenter research.
Primary feasibility outcomes are: incidence of the
index condition, the proportion of eligible patients
within the screening cohort, recruitment rate for those
deemed eligible, allocation crossover and short-term
compliance with the study protocol.
Secondary outcomes are: combined incidence of
thrombus propagation to the popliteal vein, DVT recur-
rence, development of pulmonary embolism or VTE
related sudden death during the 3-month intervention
period; incidence of major and minor bleeding episodes
during the 3-month treatment period; incidence of post-
thrombotic leg syndrome at 2 years; and incidence of
VTE recurrence at 2 years.
Outcome measures will be defined using the following
tools: DVT recurrence or development of pulmonary
embolism will be confirmed by objective diagnostic cri-
teria, either via repeat CUS in the presence of worsening
symptoms or PIOPED reported ventilation-perfusion
scan or CT pulmonary angiogram in the presence of
new chest symptoms [39]. Any cases of sudden death
during the interventional phase of the trial will be
assessed by a panel of experts blinded to treatment allo-
cation, including a Professor of Emergency Medicine,
Consultant Hematologist and Consultant Respiratory
Physician. A consensus decision will be required regard-
ing VTE as the principal cause of death.
Major bleeding episodes will be defined as standardized
in 2005 by Schulman et al.: clinically overt and associated
with a fall in hemoglobin of 20 g/l, resulting in the need
for transfusion of two or more units of red cells, invol-
ving a critical site, or fatal [42]. Minor bleeding episodes
will be subcategorized as per Schulman et al. in 2009
into clinically relevant, or nuisance bleeding [43].
Post-thrombotic syndrome will be diagnosed and
numerically graded using the validated and internation-
ally adopted Villalta scale [40].
Withdrawal, allocation crossover and protocol violation
Participants withdrawing from the study voluntarily will
be included in the intention to treat analysis. Allocation
crossover will be deemed to occur if patients allocated
to conservative treatment are prescribed full dose thera-
peutic anticoagulation for > 5 days at any stage during
3-month follow-up, or patients allocated to anticoagula-
tion have therapy withheld for > 5 days.
Data safety and monitoring board (DSMB)
The DSMB will be independent and composed of three
principal members: a leading expert in thrombosis/
hemostasis, an independent statistician and an expert in
clinical trials (chair). All pharmacovigilance reports
including serious adverse events, adverse events, proto-
col violations and allocation crossovers will be reported
to the DSMB along with all clinical endpoint data col-
lected. The group will be convened after recruitment of
50 patients. No criteria exist for early termination of the
pilot study; judgment of the DSMB will be acknowl-
edged and followed.
The board comprises: Professor Henry Kitchener
(Chair), honorary consultant gynecological oncologist
and chair of the National Cancer Research Institute’s
Gynaecological Clinical Studies Group; Dr Trevor
Baglin, consultant hematologist and President of the
British Society for Haemostasis and Thrombosis; and Dr
Steve Roberts, medical statistician and senior lecturer at
the University of Manchester.
Sample size considerations
The most recent prospective evidence estimates the 3-
month composite risk of VTE in untreated patients with
undifferentiated distal DVT to be approximately 5%
[23]. Data from separate research cites the above risk to
be 1% in patients receiving anticoagulation [16]. To
achieve this expected difference between groups, 489
patients per group would provide statistical power of
80% with a two-sided a of 0.05. For a definitive study,
the required sample size is thus currently estimated at
approximately 1,000 patients.
For the primary feasibility study we will recruit over a
16-month period initially, aiming to achieve roughly
10% of the current sample size estimate at 100 patients.
An updated power calculation will be derived from the
primary feasibility data along with refinements to trial
design for use in the definitive RCT.
Statistical analysis
As a feasibility study, principal analysis will focus on the
incidence of distal DVT as the index condition within
the screening cohort and the proportion of eligible
patients willing to participate in the trial. Protocol viola-
tions and allocation crossover rate will also be assessed
within the two groups to determine the feasibility of
maintaining treatment allocation within each cohort for
the duration of the study period. Binomial confidence
intervals will be estimated for all proportions using the
Wilson score exact method.
The predefined criteria for assessing success of feasi-
bility will constitute the following: (1) index disease inci-
dence > 5% within the screening cohort, (2) > 70%
recruitment rate within eligible participants and (3) <
25% protocol violation rate.
The secondary analysis will be a comparison of antic-
oagulation versus conservative treatment for prevention
of the secondary clinical endpoint following the ‘inten-
tion to treat’ principle. A further ‘per protocol’ analysis
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of all clinical endpoints will take place excluding all
withdrawals, allocation crossovers and protocol viola-
tions. Proportions will be compared for statistical signifi-
cance using Fisher’s exact test and a further descriptive
analysis made of the individual components forming the
composite primary outcome. An estimate will be made
with 95% confidence interval of absolute risk reduction.
Together with the primary feasibility outcomes, this data
will allow estimation of the number of sites, duration of
recruitment and resources needed to conduct the defini-
tive multicenter study.
Further intention to treat analyses of secondary and
tertiary endpoints occurring within the two groups will
be compared using Fisher’s exact test. All significance
tests will be two sided.
Discussion
Management of isolated distal DVT is controversial
throughout the developed world. Investigation and treat-
ment strategies continue to vary locally and internation-
ally. National management guidance continues to
change based on emerging evidence [44,45]. These
guidelines acknowledge the deficit in the literature and
modern papers continue to call for prospective clinical
trials [18,32,36,46]. There is a pressing and documented
need to clarify the benefits of any treatment and the
risks involved.
The ACT study has begun as a feasibility project,
recruiting over a 16-month period. The main clinical
outcomes assessed will incorporate both VTE-related
and anticoagulant-related complications. Analysis of fea-
sibility data will support future sample size calculations,
allow refinement of methodology and inform the con-
duct and coordination of an adequately powered multi-
center RCT.
Selection of the most appropriate primary outcome for
the definitive trial is scientifically challenging. We pro-
pose a composite primary outcome of VTE-related
death, DVT propagation, pulmonary embolism or major
bleeding occurring within 3 months. This outcome com-
bines the most relevant considerations for clinicians
facing the decision of whether to prescribe anticoagula-
tion for a patient with isolated distal DVT. Acknowled-
ging the current equipoise, this composite outcome
focuses on net benefit, balancing the risks of withhold-
ing anticoagulation against the risks of prescribing
anticoagulation.
Each component of this composite outcome is directly
relevant to our research question. While death is argu-
ably the most important outcome, it is not the only con-
sideration in the decision to anticoagulate. Proximal
propagation is a proxy marker for aggressive disease
and, due to the potential for death and pulmonary
embolism, it would be unethical to continue to withhold
anticoagulation in its presence. Major hemorrhage is the
main concern with therapeutic anticoagulation and lar-
gely responsible for our situation of equipoise.
The use of composite outcomes within controlled
trials is supported by international bodies [47]. Advan-
tages include the engagement of multiplicity and deriva-
tion of a clinically important result from a smaller
sample, with consequent reduction in costs and timely
introduction of appropriate treatments. Modern inter-
ventional trials in venous thromboembolic disease con-
tinue to rely on a composite of endpoints as the
primary outcome [43,48]. Disadvantages include dilution
of treatment effect, the detrimental impact of subjective
outcomes and the equal weighting that is given to fac-
tors of varying importance to patients and clinicians
[49,50]. We aim to address these concerns as follows:
(1) our composite outcome includes primarily objective
measures, (2) the composite outcome includes only
those factors that would directly influence the decision
to anticoagulate and are therefore crucial to definitively
answer our research question, and (3) all individual fea-
tures of the composite endpoint will be separately iden-
tified within the secondary clinical outcomes to allow
direct and transparent statistical comparison between
groups.
In tandem with the use of a composite outcome we
will also involve a health economist within the definitive
trial design/analysis, to assess economic merits and
overall health utility of the research question.
Other bleeding events, VTE recurrence and the devel-
opment of post-thrombotic syndrome will constitute
additional secondary outcomes. With a large dataset, ana-
lysis can also extend to search for individual factors sig-
nificantly associated with propagation within the
conservatively treated cohort. This can be achieved using
regression techniques to examine elements within the
history, examination and workup that can subsequently
be classed as predictive of adverse outcome. If significant
predictors exist, consideration can be given to develop-
ment of a decision tool aimed at helping clinicians to
decide which distal thrombi to anticoagulate. This
research is essential in developing an ideal model of risk
stratification and individualized treatment [36]. Thera-
peutic anticoagulation should be tailored to those at risk.
A definitive answer to the management questions sur-
rounding investigation and treatment of distal DVT has
huge implications for both patients and clinicians. If a
real and significant reduction in risk of complications is
seen with therapeutic anticoagulation, diagnostic strat-
egy and clinical guidance can become focused and
coherent both nationally and internationally. All patients
can subsequently receive evidence-based therapy aiming
to prevent both short and long-term complications of
disease. If the absolute risk reduction seen is deemed
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non-significant, or benefit limited by bleeding risks, then
clinicians can pursue conservative management with
confidence. Anticoagulation can be restricted in the
majority of cases, resulting in reduced healthcare costs
and bleeding complications. Either way, the ACT study
aims to benefit both patients and clinicians by providing
modern evidence to assist decision making for this chal-
lenging and relatively common clinical scenario.
Trial status
The ACT trial was conceived and designed in 2009, with
successful application for peer reviewed funding through
the College of Emergency Medicine (UK) in 2010 and
National Institute for Health Research (NIHR) portfolio
adoption in 2011. Recruitment to the trial began in Janu-
ary 2011. As of 15 January 2012, 62 patients have been
successfully recruited within a 12-month period. Steering
committee review has occurred with governance over-
sight and full approval for continued recruitment to the
end of the feasibility window. Recruitment is planned to
continue until the end of April 2012. Following protocol
completion and subsequent analysis, preliminary results
will be available towards the end of the year.
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